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Abstract
Rationale: Little is known about gender differences in plasma biomarker levels in patients with chronic obstructive
pulmonary disease (COPD).
Hypothesis: There are differences in serum biomarker levels between women and men with COPD.
Objective: Explore gender differences in plasma biomarker levels in patients with COPD and smokers without COPD.
Methods: We measured plasma levels of IL-6, IL-8, IL-16, MCP-1, MMP-9, PARC and VEGF in 80 smokers without COPD (40
males, 40 females) and 152 stable COPD patients (76 males, 76 females) with similar airflow obstruction. We determined
anthropometrics, smoking history, lung function, exercise tolerance, body composition, BODE index, co-morbidities and
quality of life. We then explored associations between plasma biomarkers levels and the clinical characteristics of the
patients and also with the clinical and physiological variables known to predict outcome in COPD.
Results: The plasma biomarkers level explored were similar in men and women without COPD. In contrast, in patients with
COPD the median value in pg/mL of IL-6 (6.26 vs 8.0, p=0.03), IL-16 (390 vs 321, p=0.009) and VEGF (50 vs 87, p=0.02)
differed between women and men. Adjusted for smoking history, gender was independently associated with IL-16, PARC
and VEGF levels. There were also gender differences in the associations between IL-6, IL-16 and VEGF and physiologic
variables that predict outcomes.
Conclusions: In stable COPD patients with similar airflow obstruction, there are gender differences in plasma biomarker
levels and in the association between biomarker levels and important clinical or physiological variables. Further studies
should confirm our findings.
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Introduction
The prevalence of tobacco-related diseases in women, mainly
chronic obstructive pulmonary disease (COPD) and lung cancer
continues to increase [1]. In the Western world, the bulk of the
increase in COPD related morbidity and mortality is driven by the
increasing burden of disease in women [2] likely related to the
historic increase of smoking among women in these areas [3].
Compared with men with similar degree of airflow obstruction,
women with COPD have worse dyspnea and quality of life scores,
lower body mass index (BMI) and fat free mass (FFM) [4], and
manifest a higher prevalence of anxiety and depression [5]. In
spite of these differences, they appear to have a better survival [6].
Several plasma biomarkers differ in their concentration between
patients with COPD and normal controls [7]. The serum level of
these biomarkers (CRP, IL-6, TNFa, MMP-9, PARC, VEGF)
have been associated with some of the clinical features of the
disease [8,9] and have been proposed to be related to the systemic
consequences of the disease [10], its progression [11] and the
association between COPD with cardiovascular disease [12] and
lung cancer [13].
In spite of the differences in the clinical expression of COPD
between women and men, surprisingly little is known about gender
differences in plasma levels of biomarkers in patients with the
disease. The identification of different biological response in men
and women to the factors known to cause COPD could help us
understand some of the different aspects of the clinical
presentation of the disease and perhaps guide us in the
development of gender specific research and possible therapy.
We hypothesized that compared with men; women with COPD
have different levels of plasma biomarkers known to be abnormal
in patients with COPD. To test this hypothesis we conducted a
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obstruction and a cohort of COPD patients attending pulmonary
clinics. Both groups consisted of equal number of men and women
of similar age and lung function. Based on our previous work [6],
we selected 8 markers representing different biological pathways
that also showed strong association with COPD. As markers of
inflammation we measured the interleukins 6, 8, and16 (IL-6,
IL-8, IL-16), tumor necrosis factor alpha (TNF a). Vascular
endothelial growth factor (VEGF) and matrix metalloproteinase
nine (MMP-9) were selected as markers of injury and repair.
Monocyte chemoattractant protein-1 (MCP-1/CCL2), and pul-
monary activation regulated protein (PARC/CCL-18) were
selected as primary chemoattractants. The level of these markers
also relates to clinical variables of importance in COPD.
Methods
Smokers without COPD and patients with COPD older than 40
years old were invited to participate in the study. The COPD
patients were part of the BODE observational study, recruited
between January 1997 and December 2008. The patients that
participated in this study were recruited in pulmonary clinics in
two tertiary university hospitals in the United States (St.
Elizabeth’s Medical Center, Boston) and Spain (Nuestra Sra de
La Candelaria, Tenerife) [14].
COPD was defined by a history of smoking at least 10 pack-years
and a FEV1/FVC ratio less than 0.7 measured 20 minutes after the
administrationof400ugofinhaledalbuterol.Patientswereexcluded
if they had a history of asthma, bronchiectasis, tuberculosis or other
confounding diseases like severe congestive heart failure (Stage II
through IV NYHA), obliterative bronchiolitis or diffuse panbronch-
iolitis. All COPD participants were clinically stable (free of
exacerbation for at least 8 weeks) and were receiving standard
medical treatment according to the ATS/ERS consensus [15].
Healthysmokers,definedbya historyofsmoking atleast10pack-
years and a FEV1/FVC ratio of more than 0.7 measured
20 minutes after the administration of 400ug of inhaled albuterol,
were also recruited in both medical centers. They did not have
known history of asthma or any other history of pulmonary disease.
The human-research review board at each site (IRB nu 258
Hospital Universitario Ntra Sra de Candelaria and IRB nu 00195
St Elizabeth’s Caritas Medical Center IRB committees) approved
the study and all patients signed the informed consent.
Clinical parameters measurements
A personal interview with trained personnel recorded the
following information: age, smoking status, pack-years history and
co-morbidities using the Charlson scale [16] where points
are assigned to the presence of different co-morbidities. The
score ranges from 0 to 37, with the higher score implying more
co-morbidity.
Pulmonary function [14]and the six minute walking distance
(6MWD) were performed following ATS guidelines [17]. Briefly, the
6MWD chosen was the better of two 6-minute walk distance tests
separated by 30 minutes in a 30 meters corridor. The inspiratory
capacity (IC) was measured as previously described and the IC/TLC
was calculated from the lung volume measurements [18].
Dyspnea was assessed using the Modified Medical Research
Council Dyspnea Scale (MMRC) [19]. The BMI was calculated as
the weight in kilograms divided by height in meters
2. Arterial
blood gases were measured at rest. The BODE index was
measured as previously described [13].
We utilized the same matching method for the COPD patients
as in other published studies [4,6]. We selected and matched the
patients from an initial sample of 138 males and 76 females with
COPD; from this cohort we were able to match every female
patient with a male with FEV1 % of predicted within 62%. When
more than one male was found to match a female, we randomly
chose the patient to be included in the final sample, being blind to
the rest of the evaluated parameters.
Biochemical analyses
Plasma of all study participants was collected into VacutainerH
tubes. Blood specimens were centrifuged (20006g), and aliquots
stored at 280uC until laboratory analysis.
Plasma levels of IL-6, IL-8, IL-16, MCP-1, MMP-9, PARC and
VEGF were measured by ELISA (R&D System, Minneapolis)
according to the manufacturer’s instructions. The detection limits
were 0.7 pg/mL, 3.5 pg/mL, 6.2 pg/mL, 5,0 pg/mL, 156 pg/mL,
10 pg/mL,and5.0 pg/mL, respectively. Thewithin-assay coefficient
of variation for all assays was less than 10%.
Statistical analysis
Quantitative measurements with parametric and non-paramet-
ric distribution are presented as mean 6 SD or median 25–75
th
percentiles, while categorical variables are presented as percent-
ages. Sex differences were explored using Student t test, Man-
Whitney U tests and Chi square test respectively. To compare sex
differences in plasma marker levels we used ANOVA test to adjust
for their pack-year history. A multiple linear regression model
determined those factors that influence each marker level. We
included in the model those factors that showed statistical
difference in the univariate analysis (DLCO and pack-years
history) and those that demonstrated associations with plasma
levels (age, gender, BMI, FEV1%). The statistical analyses were
adjusted for multiple comparisons. Significance was established as
two-tailed p-value#0.05. Calculations were made with the
statistical package SPSS Inc version 15.0 (Chicago, IL, USA).
Results
The clinical characteristics of the 80 current or former smokers
without COPD (40 males and 40 females) are shown in Table 1. No
gender differences were found in all clinical parameters evaluated
except that the smoking history was higher in men than women.
Table 1. Clinical characteristics of smokers without COPD of
both genders.
Smokers without COPD
Clinical Characteristics Males n=40 Females n=40 p Value
Age yrs*6 3 676 2 67n s
BMI Kg/m
2*2 7 662 7 64n s
Smoking Status active 52% 60% ns
Pack-years History** 44; 38–73 26; 20–50 0.042
Charlson** 0;0-0 0;0-0 ns
FEV1%*9 7 616 91615 ns
FVC%* 100615 96614 ns
BMI, body mass index. FEV1%, forced expiratory volume in one second (%
predicted).
FVC%, forced vital capacity (% predicted).
ns=non significant.
*mean6SD.
**median; 25–75
th percentiles.
doi:10.1371/journal.pone.0016021.t001
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of patients were in GOLD stages I and II and 56% in III and IV.
Their clinical and physiological characteristics are shown in
Table 2. Males and females had similar age, BMI, FEV1% FVC%,
TLC%, PaCO2, PaO2 and BODE indexes. Statistical significant
differences were found in IC/TLC, DLCO, 6MWD, MMRC and
smoking history.
Table 3 shows the plasma biomarker levels in healthy smokers
and in COPD patients, adjusting for smoking history. No statistical
differences were found in the plasma biomarker levels in healthy
men and women smokers. In patients with COPD there was a
statistically significant difference in IL-6, IL-16 and VEGF levels
between women and men. In the multivariate analysis, gender was
a statistical significant predictor of IL-16, PARC and VEGF levels.
Table 4 shows the association between plasma markers that
showed gender differences and selected clinical parameters.
Plasma levels of IL-6, IL-16 and VEGF had different strength of
associations with the clinical variables in the two genders.
Discussion
The present work has three main findings. First, there are no gender
differences in plasma biomarker levels in smokers without COPD with
similar clinical characteristics. Second, there are gender differences in
some plasma biomarker levels in patients with COPD and similar
degree of airflow obstruction. Third, there also gender differences in
the strength of the association between selected biomarkers and clinical
variables known to be associated with poor outcomes.
Several lines of evidence suggest the presence of gender
differences in plasma inflammatory cytokines levels in health
[20] as well as in disease [3]. Several factors have been implicated
as possible causes for these differences. The most important factors
thought to account for these differences include a difference in the
proportion of fat tissue and its distribution [20], and the level of
sex hormones [21]. These reported differences could influence the
way women with respiratory diseases cope with the inflammatory
response related to the disease and ultimately relate to the
development of lung cancer [22] and COPD [4,6,23].
In a well-characterized population of patients with COPD, our
group has previously shown that there are important gender
differences in the clinical presentation as well as in the survival of
men and women with COPD [4,6]. Based on these clinical
findings, we planned this cross sectional observational study to test
the hypothesis that COPD patients with similar degree of airflow
obstruction manifest gender related differences in plasma bio-
markers. The biomarkers were selected based on the results of a
previous study by our group using high throughput proteomic
analysis [9]. The final grouping included: A. inflammatory
markers (IL-6, IL-16, and IL-8); B. Injury and repair markers
Table 2. Clinical characteristics of patients with COPD.
COPD patients
Clinical Characteristics Males n=76 Females n=76 p Value
Age yrs*6 4 676 4 68n s
BMI Kg/m
2 27642 7 65n s
Smoking Status active 33% 42% ns
Pack-years history*6 9 632 57633 0.008
Charlson** 0;0–1 0;0–1 ns
MMRC** 1;0–2 2;1–3 0.033
6MWD m** 464;378–553 404;335–487 0.012
FEV1%*5 0 621 50622 ns
FVC%*8 2 622 79624 ns
TLC%*1 1 7 621 121623 ns
IC/TLC* 0.3360.09 0.2960.11 0.015
DLCO** 68;44–90 50;35–77 0.007
PaO2 mmHg*7 0 612 72612 ns
PaCO2 mmHg*4 4 674 3 66n s
BODE* 2;1–4 3;1–5 ns
BMI, body mass index. FEV1%, forced expiratory volume in one second (%
predicted).
FVC%, forced vital capacity (% predicted). MMRC, modified medical research
council dyspnea scale. 6MWD, six-minute walk distance. TLC, total lung
capacity.
IC, inspiratory capacity. BODE, body mass index, obstruction, dyspnea and
exercise capacity index.
ns=non significant.
*mean6SD.
**median; 25–75
th percentiles.
doi:10.1371/journal.pone.0016021.t002
Table 3. Plasma protein levels in smokers without COPD and COPD.
Marker IL-6 IL-8 IL-16 MCP-1 MMP-9 PARC VEGF
Smokers without COPD
Females 9.8
6.9–13.7
7.6
4.1–11.5
386
304–511
395
296–632
4485
3766–5885
39254
30954–51759
38.0
21.0–76.0
Males 8.5
6.9–10.0
5.0
2.9–7.2
495
398–647
521
331–636
3670
3175–4270
39961
29015–46794
30.9
20.1–43.7
p Value ns ns ns ns ns ns ns
COPD patients
Females 6.2
3.5–10.7
9.6
6.8–13.1
390
296–598
502
364–765
3940
2997–15262
46291
27725–57780
50.3
26.8–110.6
Males 8.08
1.9–23.3
9.2
6.3–15.9
321
226–459
511
404–648
5174
3182–14569
48400
33863–64697
87.7
33.0–171.0
p Value 0.032 ns 0.009 ns ns ns 0.022
Levels values are shown as median in pg/dL with their 25–75
th percentiles.
ns=non significant.
doi:10.1371/journal.pone.0016021.t003
Gender Differences in Biomarkers in COPD
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16021(MMP-9, VEGF) and C. markers that are thought to be chemoa-
ttractants (MCP-1, PARC).
The first observation in this study is that smokers without
COPD with similar clinical characteristics did not show gender
differences in the plasma levels of the markers measured. This is an
important and novel finding because it suggests that there are no
gender differences in those smokers that are able to handle the
injurious local and systemic response induced by tobacco
consumption once age, BMI, smoking status and co-morbidities
are controlled. Perhaps this explains the difference with previous
reports in healthy individuals where the volunteers had differences
in the baseline characteristics [21].
In contrast to the findings in non- COPD controls, we observed
that in patients with COPD there are statistically significant
gender differences in IL-6, IL-16 and VEGF. Interestingly,
different associations with important clinical or physiological
outcomes were found with the same biomarkers in each sex,
supporting a true gender role.
IL-6 is a pro-inflammatory cytokine that provides a link between
innate and acquired immunity. Increased levels of IL-6 in exhaled
breath condensate, sputum and plasma has been described in
patients with COPD. IL-6 is responsible for stimulating hepatocytes
to secrete C reactive protein and has been proposed to be
responsible for the systemic consequences of COPD (insulin
resistance, osteoporosis [24], muscle degradation [25], and
depression [26]). The plasma IL-6 levels were significantly lower
in females with COPD compared with smoking women without
COPD (p=0.01). This was not observed in males were the serum
level in both groups were similar (p=0.15). In addition, the plasma
IL-6 levels in COPD patients was significantly lower in females than
males. The clinical significance of the difference is difficult to
ascertain because this has not been determined yet and there is
variability in the serum level of this biomarker.
IL-16 is an important chemokine that regulates recruitment and
activity ofCD4lymphocytes.Littleinformation is available on plasma
levelsof IL-16 in COPDpatients. It has been related to the process of
pulmonary vascular remodeling [27]. Females in our cohort had
higher plasma IL-16 levels. The level of IL-16 was associated with
BMI in female COPD patients, but the clinical relevance of this
finding is unclear. However, this gender difference should be taken in
account when this cytokine is analysed in COPD patients.
VEGF has an important role in regulating the growth of new
vessels and vascular leakage, and has been shown to be reduced in
the lung and sputum of COPD patients. In rats, blockade of VEGF
receptor 2 (VEGF-R2) induces alveolar cell wall apoptosis and the
development of emphysema like pathology [28]. Previous studies
have shown elevated plasma levels in COPD inversely associated
with the degree of airway obstruction [9]. In the present work we
also found elevated levels of VEGF in COPD in comparison with
smokers without COPD. We also observed that gender was one of
the predictors of its plasma levels. Its levels correlated with the
BODE index in both genders and with markers of lung
hyperinflation (IC/TLC) and emphysema (DLCO) in men. These
observations suggest a different sex response in this important
growth factor that has been implicated in the development of
emphysema, a phenotype more prevalent in males [28].
There are some limitations in our study. First, we did not analyze
other important plasma markers associated with COPD (CRP,
TNF-alpha, surfactant protein D or fibronectin). We chose our
panelofplasmamarkersbasedonourgroup’sexperience,biological
plausibility and attempting to represent the multidimensional
pathological process of COPD [9]. We also acknowledge that not
all phenotypes of the disease are represented in this sample of
COPD patients and that identification of phenotypes such as
emphysema or chronic bronchitis could help in determining a
distinct plasma marker profile. However, our main goal was to
explore if gender could influence the level of plasma response and
not to comprehensively describe the plasma markers of COPD.
Although we did not find significant differences in plasma markers
levels in smokers without COPD, we acknowledge this could be due
to our sample size, which was relatively small, thereby generating a
b type II error. However, we still believe that our sample of healthy
smokers (40 males and 40 females) with similar age, BMI and
comorbidities, is a good sample to represent normal individuals.
In summary, there were no gender differences in selected
plasma biomarker levels in smokers without COPD, while in
patients with COPD there were gender differences in some
biomarker levels, especially those thought to be implicated in the
genesis of emphysema. Further, the gender differences in plasma
levels are in line with the reported gender specific clinical
manifestations of COPD. We acknowledge this to be a pilot study
that should be taken as hypothesis generating work. Further
studies measuring these and other plasma markers should confirm
the relevance of these findings.
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